Acidosis of diabetic origin; hepatic and diabetic coma, precomatous state; liver and kidney failure; respiratory acidosis in pulmonary heart failure, heart diseases accompanied by extrasystole, paroxysmal tachycardia, atrial fibrillation and other rhythm disturbances, mild forms of multiple sclerosis; preeclampsia and eclampsia; peripheral neuritis; pathological processes with impaired carbohydrate metabolism.

Increased sensitivity to cocarboxylase.

Active substance: 1 ampoule or vial contains 50 mg of cocarboxylase hydrochloride;

excipient: sodium carbonate.

Interaction with other medicinal products and other types of interactions.

Cocarboxylase enhances the cardiotonic effect of cardiac glycosides and improves their tolerability.

When carrying out complex therapy, it is necessary to take into account the property of cocarboxylase to enhance the cardiotonic effect of cardiac glycosides. in case of atrial fibrillation, the preparation should not be administered intravenously.

The effectiveness and safety of the use of cocarboxylase hydrochloride for the treatment of pregnant women or during breastfeeding have not been established, so the preparation is not recommended to be prescribed during this period.

The ability to influence the speed of reaction when driving vehicles or other mechanisms.

Was not studied.

Method of application and dosage.

usually used as a component of complex therapy. to enter intramuscularly, less often - subcutaneously or intravenously. before administration, dissolve the contents of the ampoule in 2 ml of water for injections. with intravenous injection, the volume should be brought up to 10-20 ml, with drip - up to 200-400 ml, adding 0.9% sodium chloride solution or 5% glucose solution. the dose for administration should be determined individually, taking into account the nature of the disease and the severity of the patient's condition. adults to enter 50-100 mg/day once. course of treatment - 15-30 days. if necessary (diabetic coma), the specified dose can be re-introduced after 1-2 hours. in the future, you should switch to maintenance therapy - 50 mg once a day. in case of acute renal and/or liver failure, the preparation is used intravenously as a jet of 100-150 mg (4-6 ml) 3 times a day or as a drip (in a 5% glucose solution) at 100-150 mg (4-6 ml) for 1 - 1.5 months.

Children should be given subcutaneously or intramuscularly: from birth to the third month of life - 25 mg once a day; from 4 months to 7 years - 25-50 mg once a day, 8-18 years - 50-100 mg once a day. If necessary, the specified daily doses can be administered in two doses.

Children.

Apply from birth. do not use the preparation intravenously.

Appears in the form of a more pronounced form of adverse reactions. it is recommended to stop using the preparation, symptomatic treatment aimed at normalizing breathing and the activity of the cardiovascular system.

From the side of the immune system: allergic reactions, including hypersensitivity reactions, are possible. symptoms can vary from itching, skin rash, urticaria to the development of anaphylactic shock; with intravenous administration - hyperemia, itching, swelling at the injection site.

Store in the original packaging to protect from exposure to light at a temperature not higher than 25 ºС. keep out of the reach of children.

The prepared solution should not be used with other medicinal products. use the solvent included in the package.

For 50 mg of the preparation in ampoules or vials. 2 ml of solvent in ampoules.

For 5 vials with the preparation in a blister, 2 blisters in a pack; 5 vials with the preparation and 5 ampoules with a solvent in a blister, 1 or 2 blisters in a pack.

For 5 ampoules with the preparation in a blister, 1 or 2 blisters in a pack; 5 ampoules with the preparation and 5 ampoules with a solvent in a blister, 1 or 2 blisters in a pack.

For 5 ampoules with the preparation in a blister and 5 ampoules with a solvent in a blister, 1 or 2 blisters with the preparation and 1 or 2 blisters with a solvent in a pack.